Four executives outline which industry challenges, strategic considerations, and opportunities should be top of mind as RNA therapeutics companies establish their to-do lists for 2023.
Each January, the J.P. Morgan healthcare conference helps to set the biopharma industry agenda for the coming year. What will be the next big thing in 2023?
Major regulators, including the FDA and EMA, have established frameworks through which data must be captured and exchanged with them. But your pharma, biotech, or medical device company needs a solid plan for how that data will be governed.
Explore how data science and artificial intelligence/machine learning (AI/ML) driven predictive and prescriptive insights can help research teams cut the time and cost.
Explore the key advantages of a proven approach to scale the lentiviral vector (LVV) production process (48L cf) in a bioreactor (200 L) without changing critical quality attributes (CQAs).
The number of Notices of Inspectional Observation (Forms 483 (i.e., 483s)) issued against medical device manufacturers in FY2022 was 538 compared to 191 in FY2021, an increase of almost 200%. Take a more detailed look into these 483s.
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.
Connect With Life Science Leader:
This website uses cookies to ensure you get the best experience on our website. Learn more
